(Q38614967)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26496239%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

title

Novel strategies for the diagnosis and treatment of cardiac amyloidosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26496239%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26496239%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Paolo Milani

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26496239%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

3

Giampaolo Merlini

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26496239%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

publication date

23 October 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26496239%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Cardiovascular Therapy

28 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26496239%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26496239%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26496239%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

page(s)

1195-1211

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26496239%20AND%20SRC:MED&resulttype=core&format=json

Molecular mechanisms of amyloidosis

28 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Nomenclature 2014: Amyloid fibril proteins and clinical classification of the amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Dangerous small B-cell clones.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

The repertoire of λ light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

The amyloidogenic V122I transthyretin variant in elderly black Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Fibril in senile systemic amyloidosis is derived from normal transthyretin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Liver biopsy discloses a new apolipoprotein A-I hereditary amyloidosis in several unrelated Italian families

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

The new apolipoprotein A-I variant leu(174) --> Ser causes hereditary cardiac amyloidosis, and the amyloid fibrils are constituted by the 93-residue N-terminal polypeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

A practical approach to the diagnosis of systemic amyloidoses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Strong transthyretin immunostaining: potential pitfall in cardiac amyloid typing

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Shotgun protein profile of human adipose tissue and its changes in relation to systemic amyloidoses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Diagnostic and prognostic value of low QRS voltages in cardiac AL amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Longitudinal left ventricular function for prediction of survival in systemic light-chain amyloidosis: incremental value compared with clinical and biochemical markers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Detection of left ventricular systolic dysfunction in cardiac amyloidosis with strain rate echocardiography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Differentiating cardiac amyloidosis and hypertrophic cardiomyopathy by use of three-dimensional speckle tracking echocardiography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Independent predictors of survival in primary systemic (Al) amyloidosis, including cardiac biomarkers and left ventricular strain imaging: an observational cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Prognostic significance of strain Doppler imaging in light-chain amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Left atrial myopathy in cardiac amyloidosis: implications of novel echocardiographic techniques.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Cardiovascular magnetic resonance for amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Cardiovascular magnetic resonance in cardiac amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Quantification of extracellular matrix expansion by CMR in infiltrative heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

T1 mapping and survival in systemic light-chain amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

T1 mapping for myocardial extracellular volume measurement by CMR: bolus only versus primed infusion technique

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

CMR imaging with rapid visual T1 assessment predicts mortality in patients suspected of cardiac amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Native T1 mapping in transthyretin amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Usefulness of 99mTc-DPD scintigraphy in cardiac amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

(99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Reduced myocardial 123-iodine metaiodobenzylguanidine uptake: a prognostic marker in familial amyloid polyneuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Light chain amyloidosis: the heart of the problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Treating advanced cardiac damage in light chain amyloidosis: still an unmet need

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Systemic light chain amyloidosis: an update for treating physicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Bortezomib in the treatment of AL amyloidosis: targeted therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Preclinical development of siRNA therapeutics for AL amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

One siRNA pool targeting the λ constant region stops λ light-chain production and causes terminal endoplasmic reticulum stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Unfolded protein response activation reduces secretion and extracellular aggregation of amyloidogenic immunoglobulin light chain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Outcome of liver transplantation for familial amyloidotic polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Liver transplantation in transthyretin-related familial amyloid polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Selective silencing of a mutant transthyretin allele by small interfering RNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

An overview of drugs currently under investigation for the treatment of transthyretin-related hereditary amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Safety and efficacy of RNAi therapy for transthyretin amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Synergy of combined doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Natural polyphenols inhibit different steps of the process of transthyretin (TTR) amyloid fibril formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Binding of epigallocatechin-3-gallate to transthyretin modulates its amyloidogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Effects of the main green tea polyphenol epigallocatechin-3-gallate on cardiac involvement in patients with AL amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Green tea halts progression of cardiac transthyretin amyloidosis: an observational report

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Epigallocatechin-3-gallate as a potential therapeutic drug for TTR-related amyloidosis: "in vivo" evidence from FAP mice models

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Protein folding and aggregation into amyloid: the interference by natural phenolic compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Genistein, a natural product from soy, is a potent inhibitor of transthyretin amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Carvedilol treatment reduces transthyretin deposition in a familial amyloidotic polyneuropathy mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Prevention of transthyretin amyloid disease by changing protein misfolding energetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Methods to evaluate the inhibition of TTR fibrillogenesis induced by small ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Safety and efficacy of long-term diflunisal administration in hereditary transthyretin (ATTR) amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Antibodies to human serum amyloid P component eliminate visceral amyloid deposits

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Antibody-mediated resolution of light chain-associated amyloid deposits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

AL amyloid imaging and therapy with a monoclonal antibody to a cryptic epitope on amyloid fibrils.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Widespread cardiovascular autonomic dysfunction in primary amyloidosis: does spontaneous hyperventilation have a compensatory role against postural hypotension?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Implantable cardioverter defibrillators in patients with cardiac amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Nutritional status independently affects quality of life of patients with systemic immunoglobulin light-chain (AL) amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

A prospective study of nutritional status in immunoglobulin light chain amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Cardiac transplantation for amyloid heart disease: the United Kingdom experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Cardiac transplantation using extended-donor criteria organs for systemic amyloidosis complicated by heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Left ventricular device implantation for advanced cardiac amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Heart transplantation in a 68-year-old patient with senile systemic amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Combined heart-liver transplantation: a single-center experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Combined heart and liver transplantation for familial amyloidotic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

CyBorD: stellar response rates in AL amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case–control study on 174 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

The role of minor salivary gland biopsy in the diagnosis of systemic amyloidosis: results of a prospective study in 62 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Usefulness and limitations of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Progression of cardiac amyloid deposition in hereditary transthyretin amyloidosis patients after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Natural polyphenols as modulators of TTR amyloidogenesis:in vitroandin vivoevidences towards therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Isolated heart transplantation for familial transthyretin (TTR) V122I cardiac amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

Solid Organ Transplantation in AL Amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1093936

10.1586/14779072.2015.1093936

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26496239%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1 reference